Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wow they really had to dig deep into their pockets to take on those positions
bottom????
i'll take it!
i agree, very easy to be suspicious...the only thing that is suspect is the BOD and the stock price...
it takes no volume to move this up .455
AGREED
we all know it is manipulated, there are naysayers, but by looking at the price action it is obvious
200 shares were at the ask at that price
really, AON above the ask and no fill? at what price were you at?
what are you talking about
all this POS does is go down
wonderful
Lifetech probably didn't get the call for the new ATM sale
doesn't take much to manipulate this
the bleeding doesn't end
market makers are out to rape and pillage shareholders as usual
maybe it re-balances every quarter
from twitter:
Shane Blackmon @shaneblackmon
$PPHM 880k estimated to buy on close for Russell quarterly rebalance.
Does anybody think that Dart is still in this POS
price action is awesome....not
always the wrong way
688k @ .93 is there arcx
AGREED no reason at all
Does Blackrock still have the position? Looks like Ayer has sold out according to their latest filing.
If THLD can partner why can't we??!!
Merck KGaA, Threshold To Co-Develop, Commercialize TH-302 Drug
Last update: 2/3/2012 5:45:22 AM
FRANKFURT (Dow Jones)--German chemical and pharmaceutical company Merck KGaA (MRK.XE) Friday signed a global agreement with Threshold Pharmaceuticals Inc. (THLD) to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug, used to treat certain kinds of cancer.
TH-302 is currently undergoing a Phase III clinical trial in patients with soft tissue sarcoma, a rare group of tumors that develop in the soft, supporting tissues of the body. The drug is also undergoing a randomized Phase II trial in patients with advanced pancreatic cancer, as well as clinical studies in other solid tumors and hematological malignancies, the companies said in a statement.
Merck KGaA will receive co-development rights and exclusive global commercialization rights, and will provide Threshold with an option to co-commercialize the drug in the U.S. In exchange, Threshold will receive an upfront payment of EUR19 million, along with further potential milestone payments.
The potential milestone payments total $525 million, with about $280 million in regulatory and development milestones and $245 million in sales-based milestones, Threshold Pharma said in a separate statement.
In the U.S., Threshold will be responsible for the development of TH-302 in the soft tissue sarcoma indication, while both companies will jointly develop the drug in all other cancer indications. Merck KGaA will pay 70% of worldwide development costs for TH-302.
-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com
(END) Dow Jones Newswires
February 03, 2012 05:45 ET (10:45 GMT)
looks like the people with power brought it down so they can load up at or below a $1 for one last time? maybe!
What guru are you referring to?
Let's hope so.
From twitter: Jason Napodano, CFA @JNapodano
Wow, Roth calls $PPHM their "TOP BIOTECH PICK of 2012". They have a $10 target!
Options are worthless if they never go in the money. So what's the point.
Ok. Now that dew isn't posting as often. Can we get this moving in the right direction
Dew's post on twitter yesterday:
DewDiligence Roy Friedman
$PPHM Bavituximab = $HEB Ampligen, Part Deux. Similar lofty claims for activity in manifold and disparate diseases.
completely disgusting how market markers rob shares, and don't say then don't
what a joke, down she goes
looks like they reversed the .96 market maker cross from the open
Looks like we are heading for a great close.
THIS IS PATHETIC. NO NEWS IS BAD NEWS FROM TUSTIN. BUSINESS AS USUAL.
Ayer Capital:
Jay Venkatesan
Owner, Ayer Capital Management, LP
San Francisco Bay Area
Investment Management
Current
Managing Partner at Ayer Capital Management, LP
Past
Director (Brookside Capital) at Bain Capital
Investment Analyst at Apax Partners
Business Analyst at McKinsey & Company
Education
University of Pennsylvania - The Wharton School
University of Pennsylvania School of Medicine
Williams College
Connections
288 connections
Websites
Company Website
Jay Venkatesan's Experience
Managing Partner
Ayer Capital Management, LP
January 2008 – Present (3 years 11 months)
Director (Brookside Capital)
Bain Capital
Privately Held; 501-1000 employees; Venture Capital & Private Equity industry
July 2002 – December 2007 (5 years 6 months)
Investment Analyst
Apax Partners
Privately Held; 51-200 employees; Venture Capital & Private Equity industry
June 1995 – August 1996 (1 year 3 months) New York, NY
Business Analyst
McKinsey & Company
Partnership; 10,001+ employees; Management Consulting industry
August 1993 – June 1995 (1 year 11 months)
Jay Venkatesan's Education
University of Pennsylvania - The Wharton School
M.B.A.
2000 – 2002
University of Pennsylvania School of Medicine
M.D.
1996 – 2002
Williams College
1989 – 1993
they never do
Richard Siracusa is NOT a Merrill Lynch analyst, do your due diligence.
Posted in Peregrine Pharmaceuticals (PPHM) | Comments Off
Data for 1st Line NSCLC and HCV Expected Q1’12
2nd Line NSCLC Enrollment Complete by Q4
Cotara® FDA PIII Planning Meeting in Q4
Download Full 43-Page Report with Important Disclosures: PPHM Update 09-28-11 http://lifetechcapital.com/ltc/wp-content/uploads/2011/09/PPHM-Update-09-28-11.pdf
1.) NSCLC & HCV Data Q1’12: Peregrine announced enrollment completion for the 86 patient trial of bavituximab for previously untreated NSCLC in combination with paclitaxel and carboplatin on September 8, 2011. Interim data from this trial is expected Q4 2011 with top-line tumor response data from all 86 patients to follow in Q1 2012. In addition, on September 26, 2011 Peregrine announced complete enrollment of their 66 patient, Phase II trial of bavituximb in combination with ribivirin for the treatment of previously untreated genotype-1 chronic HCV infection. The primary endpoint of the study is the proportion of patients achieving early virologic response (EVR), defined as a greater than or equal to 2 log reduction in HCV RNA after 12 weeks of treatment. Results are also expected by Q1 2012.
2.) Cotara® Phase III Planning: Peregrine reported strong interim overall median survival of 8.8 months (38 weeks) for its Phase II trial of Cotara® for the treatment of recurrent glioblastoma multiforme (brain cancer). This compares favorably to the typical patient prognosis of approximately 6 months at first relapse. Peregine plans to meet with the FDA to discuss the most appropriate Phase III trial plans in Q4 which might be conducted under a Special Protocol Assessment (SPA).
3.) 2nd-Line NSCLC Enrollment to Complete Q4: Peregrine is focusing on 2nd-line treatment of non-small cell lung cancer as their first potentially approvable indication for bavituximab. After suffering enrollment setbacks last quarter, their 120 patient Phase II study of bavituximab in combination with docetaxel in 2nd line NSCLC is now expected to complete enrollment in Q4 2011 with unblinded data in Q2 2012. The trial is currently enrolling at 50 different clinical sites in order to accomplish these targets.
4) Breast Cancer Data: On August 24, 2011 Peregrine reported the top line results from their single arm Phase II study investigating bavituximab in combination with docetaxel for the treatment of refractory advanced breast cancer. The median overall survival was 20.7 months as compared to 11.7 months for metastatic breast cancer patients treated with docetaxel alone in a study cited in the docetaxel package insert. Peregrine is still awaiting the overall survival data for another previous breast cancer single arm Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel for the treatment of advanced breast cancer. The trial met the primary endpoint of objective tumor response rate with 74% (34 of 46) of patients responding to treatment.
5.) We are maintaining Peregrine Pharmaceuticals with a Strong Speculative Buy rating and 12-18 month price target of $5.00. We continue to believe Peregrine’s anti-phosphatidylserine monoclonal antibody Bavituximab, with dual action against both tumor and viral targets, is a unique and exciting drug candidate in an era of “me-too” drugs and that their Iodine-131 monoclonal antibody Cotara® for glioblastoma also represents a unique approach in a very difficult to treat cancer. Our 12-18 month target price of $5.00 is based on 30x estimated 2015 EPS discounted 50% for cumulative risk. (see Financial Model Assumptions)
Download Full 43-Page Report with Important Disclosures: PPHM Update 09-28-11